Prefilled Syringes Market Size, Share & Industry Analysis, By Material (Glass and Plastic), By Closing System (Staked Needle System, Luer Cone System, and Luer Lock Form System), By Product (Complete Syringe Set and Components & Accessories), By Design (Single-chamber, Double-chamber, and Multiple-chamber), By End-user (Pharmaceutical & Biotechnology Companies, Contract Research & Manufacturing Organizations, and Others), and Regional Forecast, 2025-2032

The global prefilled syringes market size is projected to grow from USD 9.59 billion in 2025 to USD 20.62 billion by 2032, exhibiting a CAGR of 11.6%. In 2024, the market was valued at USD 8.70 billion. Europe dominated the prefilled syringes market with a share of 37.35% in 2024.

Prefilled syringes are injectable drug delivery containers designed to administer drugs via the parenteral route. There are several advantages associated with these syringes, such as reduced chances of contamination, prevention of drug wastage due to overfilling, eliminating of dosing errors, enabling quick drug delivery in case of emergencies, and easy use. Owing to the advantages mentioned above, pharmaceutical companies are considering them as one of the most effective ways of delivering a wide range of injectable drugs, including biologics and biosimilars.

The rising incidence of chronic diseases, such as diabetes and other autoimmune diseases, is likely to fuel the demand for prefilled syringes in the forthcoming years. For instance, according to the American Autoimmune Related Diseases Association Inc. (AARDA), about 50 million Americans suffer from autoimmune disorders currently. There are more than 100 autoimmune disorders, and they are among the top 10 leading causes of death among American women. The growing demand for biological drugs and innovations in pre-fillable syringe technologies to fulfill the unmet needs for treating chronic diseases across the globe is likely to support global market growth. Combined with this, the increasing number of product launches by key players and the high adoption of the products by healthcare professionals are factors likely to boost the market during the forecast period. 

The COVID-19 pandemic positively impacted the market owing to the high demand for pre-filled products. Increased production of coronavirus vaccines led manufacturers to focus on increasing their production capacity for pre-filled products. Thus, increased production capacity resulted in increased revenue among manufacturers and, therefore, positively impacted the market.

Global Prefilled Syringes Market Overview:

Market Size:

• 2024: USD 8.70 billion


• 2025: USD 9.59 billion


• 2032: USD 20.62 billion


• CAGR: 11.6% (2025–2032)

Regional Dominance:

• Europe led in 2024 with a 37.35% market share, followed by North America and the Asia Pacific.

Key Growth Drivers:

• Rise in chronic diseases (e.g., autoimmune disorders, diabetes)


• Increasing use of biologics and biosimilars


• Technological innovation in prefillable syringes


• High adoption of self-injection devices


• Impact of COVID-19 driving demand for vaccine-ready injectables

Trends:

• Shift from chemical-based drugs to biologics and biosimilars


• Patient preference for pre-filled pens over traditional syringes


• Investment and innovation in self-administration devices

Challenges/Restraints:

• Product recalls due to impurities, sterility issues, clogging needles


• Complex manufacturing processes and stringent regulations

Segment Insights:

• Material: Glass leads in 2024; plastic is growing rapidly due to BFS technology


• Closing System: Luer lock form gaining traction for safety and leak prevention


• Product: Complete syringe sets dominate; component sales moderate


• Design: Single-chamber still dominant; double-chamber gaining momentum


• End-User: Pharmaceutical & biotech firms are the primary consumers

Key Players:

BD, Gerresheimer AG, SCHOTT AG, West Pharmaceutical Services Inc., NIPRO, AptarGroup, Terumo, Helvoet, etc.

Notable Developments:

• Multiple FDA approvals (e.g., Cosentyx, Tezspire, Idacio)


• Product launches like BD Effivax and PLAJEX syringes


• Investments in production capacity (e.g., WuXi Biologics, Delpharm)

Prefilled Syringes Market Trends

Increasing Demand for Biologics and Biosimilars in the Market

The global life science industry is facing a drastic shift from chemical-based drugs to biologics and biosimilars. Biologics are excellent for targeted delivery and are less prone to drug-drug interaction, leading to increased inclination. The rise in biologics to treat chronic diseases has urged drug and packaging manufacturers to seek more sophisticated container closures and drug delivery systems.

• For instance, according to data published by BIOLOGICS HQ in 2023, there were 40 FDA-approved biosimilars. Also, according to a study published in the American Journal of Managed Care (AJMC), in April 2022, over 90% of patients preferred biosimilar delivery with a pre-filled pen versus a syringe. The study compared the adalimumab biosimilar PF-06410293 to the E.U. reference product (Humira) in rheumatoid arthritis (R.A.) and evaluated the usability of pre-filled pens (PFP) by patients and their caregivers.

Therefore, this has led to a significant increase in the use of these syringes for safely delivering biologics and biosimilars.

Request a Free sample to learn more about this report.

Prefilled Syringes Market Growth Factors

Growing Innovations in Pre-filled Products for Biologic Drugs to Propel Market Growth

Growing demand for biologics is resulting in the introduction of innovative injectable drug delivery solutions. This innovation is creating a huge demand for prefilled syringes in the market. This, along with manufacturers' growing focus on receiving regulatory approvals, is likely to support the global prefilled syringes market's growth during the forecast period.

• In October 2023, Novartis AG received the U.S. FDA approval for Cosentyx as the first biologic treatment option for hidradenitis suppurativa patients among adult patients. Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS.

Additionally, the rising prevalence of cancer, autoimmune diseases, and other non-communicable diseases is likely to increase the demand for biological drugs. For instance, according to the International Agency for Research on Cancer (IARC), by 2040, the global burden of cancer is expected to grow to 27.5 million new cases. Moreover, according to the National Stem Cell Foundation (NSFC), around 4.0% of the world population is affected by any autoimmune disease, and the most common are lupus, type 1 diabetes, multiple sclerosis, etc. This number is expected to rise in the future, leading to increased demand for biologics.

Rising Adoption of Self-Injecting Parenteral Devices to Spur Market Growth

The use of pre-filled injections as a self-injecting device is the modern way to administer parenteral drugs. These are convenient and help ease the administration process. These products help provide greater patient safety and reduce exposure to toxic products while drawing medications from the drug vials. Therefore, self-injecting devices with their pre-measured dosage reduced dosing errors and increased patient safety, offering multiple advantages for the user.

Owing to the advantages associated with these devices, healthcare providers are increasingly preferring prefilled syringes. Many companies are investing in R&D to develop innovative drugs that can be delivered through these syringes, enabling self-injection.

• For instance, in February 2023, the FDA announced the approval of Tezspire (tezepelumab), a human monoclonal antibody developed by AstraZeneca in collaboration with Amgen. The drug is the only biologic approved for severe asthma in the U.S. for self-administration in a pre-filled, single-use pen for patients aged 12 years and older.

Thus, such increasing adoption leading to new product approvals bodes well for the growth of the global market.

RESTRAINING FACTORS

Complex Manufacturing Process and Product Recalls to Hamper Market Growth

Prefilled syringes are becoming an increasingly attractive option for complex biotechnology products. However, various product recalls due to certain impurities or leakage in the syringes restrict the market growth during the forecast period.

• In May 2023, Sun Pharma recalled over 24,000 prefilled syringes of generic medication in the U.S. due to impurities found in these syringes.


• In July 2022, Nephron Pharmaceuticals Corporation, a U.S.-based company, recalled 20 prefilled syringes containing medicines such as ketamine, epinephrine, and oxytocin. The reason for the recall was a lack of assurance of sterility. Similarly, in March 2022, Adamis Pharmaceuticals Corporation announced the voluntary recall of SYMJEPI (epinephrine) Injections of 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL). SYMJEPI is a pre-filled single-dose syringe that witnesses clogging needles that obstruct the proper drug dispensing.

Thus, strict regulatory requirements, manufacturing complexity, and rising recalls of these products are major restraining factors for the market’s growth.

Prefilled Syringes Market Segmentation Analysis

By Material Analysis

Rise in Technological Innovations to Drive Plastic Segment Growth

Based on material, the market is segmented into glass and plastic. Among them, the glass segment held a significant market share in 2024. It is a highly preferred material for manufacturing due to the substantial barrier property of the glass. Also, it has the advantage of being highly compatible with several filling drug machines. Therefore, increasing focus of key players toward launching new glass pre-filled syringes is likely to support the growth of the segment in the market.

• For instance, in September 2022, BD launched BD Effivax Glass Prefillable Syringe with an aim to create required efficiencies in end-to-end production.

The plastic segment is anticipated to grow significantly during the forecast period due to key players involved in developing plastic syringes and producing technological innovations offering advantages over glass syringes.

• For instance, in May 2022, ApiJect Systems, Corp. raised USD 111.0 million in a private investment round led by Royalty Pharma and Jefferies Financial. The funds were to be used to develop ApiJect's blow-fill-seal (BFS) plastic profiled injection system and for other “general working capital” purposes.

By Closing System Analysis

Rising Technological Advancements in Luer Lock Form System to Exhibit Significant Growth Rate in the Market

Based on the closing system, the market is segmented into a staked needle system, a luer cone system, and a luer lock form system. Among closing system, the staked needle system segment captured a significant share in the market owing to the speedy usage of the staked needle system. However, the rising incidence of needle-stick injuries is likely to reduce the growth rate of the staked needle system segment in the coming years.

Technological advancements in the Luer lock form systems make them more secure by preventing needle stick accidents. Moreover, the twisting mechanism forming a locked connection in the Luer lock form system has reduced the leakage of liquid drugs. Such technological advancements, along with new product launches, further augment the segment growth at a faster pace during the forecast period.

• For instance, in June 2022, Terumo Pharmaceutical Solutions launched PLAJEX 0.5mL, a Luer Lock Silicone oil-free pre-fillable syringe for low-dose applications such as ophthalmic drugs.

By Product Analysis

Increasing Demand for Complete Syringe Lead the Segment to Hold Lion’s Share in Global Market

Based on product, the market is segmented into complete syringe set and components & accessories. Among products, the complete syringe set segment captured a significant share of the market owing to the growing demand for these products for effective drug delivery and rising demand for self-injectable delivery systems among patients.

• For instance, in January 2023, Wirthwein Medical launched a complete syringe set with prefillable plastic syringes with a Luer-lock connection.

The components & accessories segment is expected to witness moderate growth in the market in the forthcoming years. This is attributed to the lower demand among drug manufacturing companies for independent components for pre-filled injections compared to the complete set.

By Design Analysis

Increasing Approval of Single Chamber Prefilled Syringes to Capture the Largest Market Share

Based on design, the market is segmented into single-chamber, double-chamber, and multiple-chamber. The single-chamber segment captured a significant share of the market and is likely to exhibit a significant CAGR during the forecast period.

• For instance, in September 2022, Otsuka Pharmaceutical Co., Ltd. and H. LUNDBECK A/S received the USFDA's acceptance of the NDA for Aripiprazole, a long-acting injectable provided in a single-chamber-type pre-filled syringe, to treat schizophrenia and bipolar I disorder in adults.

Moreover, the growing technological innovations and shifts in preference from single-chamber syringes to a double-chamber system are likely to enhance the demand for the double-chamber system during the forecast period. Double-chamber syringes are highly efficient for storing biological components that cannot retain their stability for a longer period. Also, the growing penetration of lyophilized drugs worldwide is likely to surge the demand for these syringes during the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By End-User Analysis

Growing Interest in Injectables is leading the Pharmaceutical & Biotechnology Companies Segment to Dominate the Market

Based on end-user, the market is categorized into pharmaceutical & biotechnology companies, contract research & manufacturing organizations, and others. Among end users, the pharmaceutical & biotechnology companies segment captured a major share of the global market. The fast-expanding pharmaceutical companies across the globe are majorly engaged in biologics, vaccines, and biosimilars. These companies have increased their demand for new drug delivery systems, such as syringes, prescribed with a unit dose of medication for better patient compliance.

Moreover, a rising number of early-stage and government-funded biotech players are focusing on drug discovery and development, which is likely to boost the demand for syringes for the effective delivery of drugs. The rise in demand for innovative injectable drug delivery systems is expected to boost the pharmaceutical and biotechnology companies’ segment growth during the forecast period.

The contract research & manufacturing organizations segment is likely to expand at a significant rate during the forecast period due to innovative technologies offering filling services.

REGIONAL INSIGHTS

Geographically, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

To get more information on the regional analysis of this market, Request a Free sample

Europe dominated the global market and generated a revenue of USD 3.52 billion in 2024.  The increasing number of patients using biologics as treatment options for chronic diseases and the strong adoption of advanced delivery methods for self-injection of drugs are the major factors likely to boost the demand in Europe. In addition, the presence of key players engaged in developing pre-fillable syringes in Europe is likely to boost market growth.

• In November 2022, Schreiner Group and SCHOTT Pharma launched a pre-filled syringe with RFID. This enabled optimized processes in hospital inventory management.

North America is likely to hold the second-largest market share after Europe, owing to the rise in several chronic diseases, such as diabetes and rheumatoid arthritis. These diseases are likely to enhance the demand for prolonged drug administration at an accurate dosage. Increasing product launches and the growing presence of leading players with strong distribution networks are likely to boost market growth in North America.

The Asia Pacific prefilled syringes market is likely to witness fast-paced growth during the forecast period, majorly owing to the increasing prevalence of chronic and lifestyle diseases, rising usage of these syringes, and rapidly growing patient population. Moreover, the rising awareness regarding innovations in these syringes and significant growth in contract manufacturing companies outsourcing packaging & filling services are likely to play a pivotal role in boosting the market growth in the region.

Latin America the Middle East, and Africa regions are likely to experience slow growth in this market due to lower awareness about innovative products and slow penetration.

Key Industry Players

Strong Product Offerings by Key Players to Propel Market Growth

Becton Dickinson and Company (B.D.), Gerresheimer AG, SCHOTT AG, and West Pharmaceutical Services Inc. accounted for most of the global prefilled syringes market share in 2024. These players are likely to continue their dominance and generate significant revenue in the forthcoming years. Dominance is attributable to the robust research activities and continuous investments in innovative product development to launch a cost-effective and highly effective parenteral drug delivery system.

• For instance, in May 2023, SCHOTT AG launched pre-filled polymer syringes for deep-cold drugs with an aim to strengthen its product portfolio.

Moreover, a strong focus on strategic partnerships with other key market players is likely to support expanding their footprints in the global market. For instance, in May 2022, B.D. announced its collaboration with Mitsubishi Gas Chemical Company, to investigate the potential uses of Oxycapt technology developed by Mitsubishi Gas Chemical Company for the development of prefilled syringes.

List of Top Prefilled Syringes Companies:

• BD (U.S.)


• Gerresheimer AG (Germany)


• SCHOTT AG (Germany)


• West Pharmaceutical Services Inc. (U.S.)


• Helvoet Rubber & Plastic Technologies BV (Netherlands)


• NIPRO (Japan)


• AptarGroup, Inc. (U.S.)


• Terumo Corporation (Japan)

KEY INDUSTRY DEVELOPMENTS:

• May 2023: BD expanded the availability of all-in-one flush pre-filled syringes to support a significant reduction in microbial growth associated with catheter-related bloodstream infections among patients.


• December 2022 – Fresenius Kabi AG received the U.S. FDA approval for biosimilar Idacio (adalimumab) for the treatment of chronic autoimmune diseases. The drug is available in a self-administered pre-filled syringe combined with a self-administered pre-filled pen.


• September 2022: BD launched a next-gen prefillable vaccine syringe for efficient vaccine delivery. This helped the company to increase its brand presence.


• June 2022: WuXi Biologics, a global contract research, development, and manufacturing organization (CRDMO), launched the operation of its new drug facility, DP5, with an aim to manufacture 17 million units of pre-filled syringes each year.


• April 2022: Delpharm invested USD 30.3 million in a sterile line with an aim to manufacture prefilled syringes in France.

REPORT COVERAGE

The global market report provides detailed information regarding various insights into the market. Some of them are growth drivers, restraints, competitive landscape, regional analysis, and challenges. It further offers an analytical depiction of the market trends and estimations to illustrate the forthcoming investment opportunities. The market is quantitatively analyzed from 2019-2032 to provide the financial competency of the market. The information gathered in the report has been taken from several primary and secondary sources.

To gain extensive insights into the market, Request for Customization

Report Scope & Segmentation